Provided by Tiger Fintech (Singapore) Pte. Ltd.

CRISPR Therapeutics AG

41.36
+0.08000.19%
Pre-market: 42.110.7500+1.81%08:34 EDT
Volume:2.02M
Turnover:83.23M
Market Cap:3.57B
PE:-9.16
High:41.74
Open:40.28
Low:40.00
Close:41.28
Loading ...

CRISPR Therapeutics AG Held Annual General Meeting of Shareholders

Reuters
·
10 Jun

Crispr Therapeutics AG: Stock Soars Amid Bullish Trends

TIPRANKS
·
07 Jun

CRISPR Therapeutics AG Files Initial Beneficial Ownership Statement for Director Morrison Briggs

Reuters
·
07 Jun

Crispr Therapeutics call volume above normal and directionally bullish

TIPRANKS
·
06 Jun

Bernstein Reaffirms Their Hold Rating on Crispr Therapeutics AG (CRSP)

TIPRANKS
·
06 Jun

BEAM Up on FDA's Orphan Drug Status for Gene-Editing Therapy

Zacks
·
04 Jun

Can CRISPR Build on Casgevy's Success With Its In Vivo Pipeline?

Zacks
·
04 Jun

Promising Growth and Diversification Drive Buy Rating for Crispr Therapeutics AG

TIPRANKS
·
04 Jun

The 2 Smartest Beaten-Down Biotech Stocks to Buy on the Dip

Motley Fool
·
02 Jun

New Hope for Strokes And Heart Attacks -- Barron's

Dow Jones
·
31 May

CRISPR Therapeutics AG's Chief Medical Officer Naimish Patel Reports Disposal of Common Shares

Reuters
·
31 May

Cathie Wood’s ARK Investment buys 294K shares of Crispr Therapeutics today

TIPRANKS
·
30 May

Heart Disease Could Be a Goner When These New Drugs Arrive -- Barrons.com

Dow Jones
·
29 May

Strokes and Heart Attacks Kill. New Drugs Are Coming to Prevent Them. -- Barrons.com

Dow Jones
·
23 May

Mizuho Securities Reaffirms Their Buy Rating on Crispr Therapeutics AG (CRSP)

TIPRANKS
·
22 May

Crispr Therapeutics Price Target Maintained With a $86.00/Share by JMP Securities

Dow Jones
·
21 May

Mizuho Cuts Price Target on CRISPR Therapeutics to $85 From $99, Keeps Outperform Rating

MT Newswires Live
·
21 May

Crispr Therapeutics call volume above normal and directionally bullish

TIPRANKS
·
21 May

Strategic Growth and De-risking: Gil Blum’s Buy Rating on Crispr Therapeutics AG

TIPRANKS
·
20 May

Truist Financial Remains a Buy on Crispr Therapeutics AG (CRSP)

TIPRANKS
·
20 May